Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 1–2, pp 10–13 | Cite as

Schwerpunkt Amyloidose

Amyloidose: Einführung und Diagnostik

  • Timon HansenEmail author
schwerpunkt

Amyloidosen sind Erkrankungen, bei denen fehlgefaltete Proteine als unlösliche Fibrillen im Körper abgelagert werden und die betroffenen Organe schädigen. Lesen Sie im Folgenden, über Pathogenese, Diagnostik und Unterscheidung verschiedener Amyloidoseformen. Dabei liegt der Fokus auf den häufigeren Amyloidoseformen Leichtketten(AL)-Amyloidose und Transthyretin(Wildtyp-ATTR)-Amyloidose.

Literatur

  1. 1.
    Merlini G et al. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011 May 10;29(14):1924–33CrossRefGoogle Scholar
  2. 2.
    Merlini G et al. Immunoglobulin light chain amyloidosis. Expert Rev Hematol. 2014;7(1):143–56CrossRefGoogle Scholar
  3. 3.
    Hawkins PN et al. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323(8):508–13CrossRefGoogle Scholar
  4. 4.
    Bodin K et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468(7320):93–7CrossRefGoogle Scholar
  5. 5.
    Sipe JD et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209–13CrossRefGoogle Scholar
  6. 6.
    Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520–30CrossRefGoogle Scholar
  7. 7.
    Kyle RA et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817–22.PubMedGoogle Scholar
  8. 8.
    Utz JP et al. Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med. 1996;124(4):407–13.CrossRefGoogle Scholar
  9. 9.
    Merlini G et al. CyBorD: stellar response rates in AL amyloidosis. Blood. 2012;119(19):4343–5CrossRefGoogle Scholar
  10. 10.
    Mahmood S et al. Update on treatment of light chain amyloidosis. Haematologica. 2014;99(2):209–21CrossRefGoogle Scholar
  11. 11.
    Merlini G et al. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124–30CrossRefGoogle Scholar
  12. 12.
    Kyle RA et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9CrossRefGoogle Scholar
  13. 13.
    Maurer MS et al. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357–77CrossRefGoogle Scholar
  14. 14.
    Tanskanen M et al. Senile systemic amyloidosis affects 25 % of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–9CrossRefGoogle Scholar
  15. 15.
    Maurer MS et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007–16CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Hämatologisch-Onkologische Praxis Altona (HOPA) MVZ GmbHHamburgDeutschland

Personalised recommendations